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ABSTRACT
Background and Objectives: EUS guided core biopsy was once rarely performed but is now entering mainstream practice.
Neuroendocrine tumors often warrant core biopsy as sufficient tissue must be obtained to allow for special staining to ensure
a correct diagnosis. Traditionally these lesions were sampled with FNA needles. We performed a retrospective pilot study to
evaluate the clinical value and efficacy of the a new EUS core needle biopsy needle as compared to a standard EUS FNA needle
in the evaluation of patients with known or suspected neuroendocrine tumors. Methods: A retrospective analysis of the first 10
patients (between January 2015 and April 2016) to undergo EUS-FNA with the SharkCore® needle at the University of Utah
School of Medicine/Huntsman Cancer Center with neuroendocrine tumors. Each case was retrospectively reviewed by a board
certified cytopathologist (BLW) for the following cytologic parameters on the aspirate smears or touch/squash preparations:
overall cellularity [1 (low) to 3 (high)], percentage of obtained cells that were lesional/representative (<25%, 26%-50%, and
>50%), relative ease of interpretation [1 (difficult) to 3 (easy)]. Pathologic material and reporting records were also reviewed
for each case to confirm the number of needle passes to achieve diagnostic adequacy, the presence or absence diagnostic
material on H&E slide (from cell block, if prepared), whether a definitive diagnosis was able to be rendered, and the presence
or absence of a true core/core fragments (within the cell block, if prepared). Results: A total of 20 patients underwent EUS-FNA
for suspected neuroendocrine lesions. Ten patients underwent either transgastric or transduodenal EUS-FNA with the 22 gauge
SharkCore® needle. The comparison cohort of 10 patients underwent either transgastric or transduodenal EUS-FNA with the
standard 22 gauge Echotip® needle. The SharkCore® needle required a fewer mean number of needle passes to obtain diagnostic
adequacy than the Echotip® (P=0.0074). For cases with cell blocks, the SharkCore® needle produced diagnostic material in
100% of cases, whereas Echotip® produced diagnostic material in 60% of cases. There was no significant difference between
specimen cellularity, percentage of lesional material, or ease of interpretation between the two needle types. Conclusion: Our
pilot investigation targeting patients with known or suspected pancreatic NETs indicates that the SharkCore® needle shows
promise in obtaining suitable tissue for ancillary testing that can allow for more definitive pathologic interpretations on EUS
FNA specimens. Fewer passes were needed with the core needle when compared to a standard needle.
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INTRODUCTION
Over the past two decades, EUS‑FNA has been
the most reliable method for sampling a variety
of gastrointestinal lesions including solid and
cystic pancreatic masses. This technique has been
shown to have a high sensitivity (75%–92%) and
specificity (82%–100%). [1] A number of different
EUS‑FNA needles are available, most being designed
to obtain cytologic specimens for either aspiration
smears or needle rinse specimens. These standard EUS
needles work with a high level of clinical efficacy,
and meaningful differences between needle types and
sizes have been difficult to identify despite extensive
efforts to determine which needle type and size is
ideal.[2‑4] Similarly, variations in FNA technique (e.g., use
or lack of use of a stylet) have also been shown to
have relatively limited impact on final results despite
widespread personal preferences among endoscopists.[5,6]
Recently, a new EUS needle (SharkCore ®, Beacon
Endoscopic, Newton, MA, USA), has been introduced.
This device has a novel tip shape designed to improve
tissue yield and to potentially obtain a core histologic
tissue sample through EUS. The design incorporates
two sharp points of different lengths and a multifaceted
bevel in an attempt to capture additional (preferably
in a core) tissue. Our group recently published a
study comparing our experience with the 22‑gauge
SharkCore® needle to a standard 22‑gauge Echotip ®
needle. Our study showed a trend toward increased
production of diagnostic material within prepared
cell blocks for the SharkCore ® needle compared to
the standard needle. [7] In 12 out of 15 pilot cases,
EUS‑FNA procedures with the SharkCore ® needle
produced actual tissue cores (or core fragments)
compared to no tissue cores with the standard needle.[7]
While the diagnosis of pancreatic adenocarcinoma can be
reliably reached based on cytologic preparations (aspirate
smears)[8] with good interobserver agreement among
cytopathologists,[9] the interpretation of tissue obtained
from patients with suspected pancreatic neuroendocrine
tumors (NETs) may be more problematic. A recent
15‑year retrospective study conducted at our institution
on the accuracy of diagnosing pancreatic NETs by
EUS‑FNA revealed that the method had only 66%
sensitivity. By comparison, the detection rate for
pancreatic adenocarcinomas was 88% over the same
time period. [10] In addition, immunohistochemical
staining of representative lesional material is often
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needed to make a definitive diagnostic interpretation for
NETs because they share overlapping cytomorphologic
features with acinar cell carcinoma, solid pseudopapillary
neoplasm, pancreatoblastoma, and even adenocarcinoma.
In reference to this, the Papanicolaou Society of
Cytopathology Guidelines advises performing ancillary
immunohistochemical stains not only for the cytologic
diagnosis of pancreatic NETs but also to aid in awarding
these tumors with an accurate grade (by Ki‑67 index).[11]
We performed a retrospective pilot study to evaluate
the clinical value and efficacy of the SharkCore® needle
as compared to a standard EUS‑FNA needle in the
evaluation of patients with known or suspected NETs.
METHODS
A retrospective analysis of the first ten
patients (between January 2015 and April 2016) to
undergo EUS‑FNA with the SharkCore® needle at the
University of Utah School of Medicine/Huntsman
Cancer Center with NCTs appearing either in the
diagnostic line or within the diagnostic comment section
was performed. For comparison, a parallel group of the
ten most recent preceding patients receiving the same
diagnostic impression who underwent EUS‑FNA by the
same endoscopists using a standard needle (EchoTip®,
Wilson‑Cook, Winston‑Salem, NC, USA) were included
in the study. The latter specimens were collected
between January 2010 and December 2014. This study
was approved by the Institutional Review Board at the
University of Utah/ARUP Laboratories.
EUS‑FNA with both needle types was performed
in the standard manner using linear endoscopes and
procedures were performed by two endosonographers,
with one (DGA) with over 15 years of experience,
acting as the operator in 18 out of the 20 cases. The
technique for both needles was to insert the needle and
take several slow passes whereas the stylet was slowly
withdrawn (referred to as the “slow pull” technique).
Rapid on‑site evaluation (ROSE) by a cytopathologist
was performed on all of the twenty included cases.
Slides were prepared for on‑site evaluation using the
rapid Diff‑Quik® stain, whereas alcohol‑fixed slides were
submitted for Papanicolaou staining. For the standard
needle specimens, FNA direct smears were created at
the time of the examination and excess needle rinse, if
present, was submitted into a saline tube for cell block
preparation. For the SharkCore® specimens, either touch
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or squash preparation slides were created, and the core (or
core fragments) was submitted in formalin fixation for
cell block preparation. The techniques for on‑site slide
preparations were either to move the core/core fragments
around the surface of the slide with a needle cap or gently
press the sample between two slides and then put the
core/core fragments into formalin (touch PREP method).
The squash preparation entails compressing the core/core
fragments between two slides and using shear force (in the
direction of the long axis of the slides) to help disperse
cells for on‑site cytologic evaluation. This method typically
disrupted the core/core fragments to the extent that no
remaining tissue fragments were available to be placed
into fixative. In some cases, one or more passes from the
SharkCore® needle were placed directly into formalin and
cell blocks were prepared. This technique was employed
only after adequate lesional tissue was obtained on a prior
touch preparation or squash prepared slide during on‑site
cytologic evaluation.
Each case was retrospectively reviewed by a board
certified cytopathologist (BLW) for the following
cytologic parameters on the aspirate smears or
touch/squash preparations: overall cellularity (1 [low] to
3 [high]), percentage of obtained cells that were lesional/
representative (<25%, 26%–50%, and >50%), and
relative ease of interpretation (1 [difficult] to 3 [easy]).
Pathologic material and reporting records were also
reviewed for each case to confirm the number of needle
passes to achieve diagnostic adequacy, the presence or
absence of diagnostic material on hematoxylin and eosin
slide (from cell block, if prepared), whether a definitive
diagnosis was able to be rendered, and the presence
or absence of a true core/core fragments (within the
cell block, if prepared). The cytologic parameters of
cellularity, production of diagnostic material in cell
blocks, and production of core/core fragments were
evaluated using Fisher’s exact test. The number of passes
was evaluated using the paired t‑test.
RESULTS
A total of twenty patients underwent EUS‑FNA for
suspected neuroendocrine lesions. Ten patients underwent
either transgastric or transduodenal EUS‑FNA with the
22‑gauge SharkCore® needle between January 2015 and
February 2016. Seven patients underwent EUS‑FNA
evaluation for solid pancreatic masses, one for a solid
duodenal wall mass, and two patients underwent
EUS‑FNA evaluation for peripancreatic lymphadenopathy.
The comparison cohort of ten patients underwent

either transgastric or transduodenal EUS‑FNA with
the standard 22‑gauge Echotip® needle. Nine patients
in this group underwent EUS‑FNA evaluation for
solid pancreatic masses and one had the procedure for
peripancreatic lymphadenopathy. All cases (except for
one deemed less than optimal with the standard needle)
were deemed satisfactory for interpretation during ROSE.
There were no adverse events seen in any patient.
The SharkCore® needle required a fewer mean number
of needle passes to obtain diagnostic adequacy than the
Echotip® (P = 0.0074). The SharkCore® needle required
a mean of 1.5 passes to reach adequacy whereas the
Echotip® required a mean of 2.9 passes [Table 1].
All twenty cases had cell blocks prepared. With
regard to cell blocks, the SharkCore® needle showed
a trend toward increased material within the cell
blocks (P = 0.0867). For cases with blocks, the
SharkCore ® needle produced diagnostic material in
100% of cases, whereas Echotip® produced diagnostic
material in 60% of cases. Eight of the ten cell blocks
made using the SharkCore® contained either cores or
core fragments within the block, whereas the remaining
two had scant diagnostic material comprised mostly of
single lesional cells. All six of the successful cell blocks
using the Echotip® needle had cohesive fragments of
diagnostic tissue [Table 2]. All cases with diagnostic
tissue in the cell block had immunohistochemical stains
Table 1. Comparison of needle passes for
SharkCore® needle and EchoTip® needle
Passes
1
2
3
4
5
Total

EchoTip®

SharkCore®

Total

1
4
2
1
2
10

5
5
0
0
0
10

6
9
2
1
2
20

Each line shows the number of cases for each number of needle passes. For
example, 4 EchoTip® cases and 5 SharkCore® cases achieved adequacy after
two needle passes

Table 2. Production of diagnostic material in cell
blocks
Diagnostic material produced

EchoTip® SharkCore® Total

Yes
Cores/core fragments/large clusters
Single cells only
No
Total

6
6
0
4*
10

10
8
2
0
10

16
14
2
4
20

The asterisk under the EchoTip® is there to specify that 2 out of the cases
in this group had no cell block prepared and 2 had no diagnostic tissue in
the prepared block
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performed to support the cytodiagnosis including
all ten cases using the SharkCore® needle. Figure 1
shows photomicrographs of cell block material from
a representative case using the each needle type.
Figures 2 and 3 show cytologic preps with the standard
needle and SharkCore®, respectively.
In terms of diagnostic reporting between the two
groups, 9/10 cases using the SharkCore® needle were
reported as NET or consistent with NET, whereas the
remaining case was called “neoplastic cells present, favor
NET.” In cases performed using the standard needle,
5/10 cases were reported as NET or consistent with
NET, 4/10 were designated as favor NET, and one was
reported as tumor cells present (with NET listed in the
differential diagnosis in the comment section).
Clinical and pathologic follow‑up for the SharkCore®
group showed that 2/10 patients had subsequent
resections confirming NETs, 4/10 had clinical
progression of disease including metastases, and 4/10
have clinically stable disease on imaging and are being
managed by surveillance. Follow‑up for the Echotip®
group showed that 2/10 patients had subsequent
resections confir ming NET, 2/10 had clinical
progression of disease including radiologic metastases,
2/10 had clinically stable disease on surveillance, one
died of unrelated causes, and 3 were lost to follow up.
In terms of the retrospectively assessed cytologic
parameters on the aspirate smears and touch/squash
preparations, there was no significant difference between
specimen cellularity, percentage of lesional material,

a

b

c

d

Figure 1. (a) Lesional core material from a case using the SharkCore®
needle (H and E, ×10). (b) Synaptophysin stain on the same tissue
block. (c) A large cluster of lesional tissue from a case using the standard
needle (H and E, ×10). (d) Synaptophysin stain on the same tissue block
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or ease of interpretation between the two needle
types (based on a blinded review by a practicing, board
certified cytopathologist).
DISCUSSION
This pilot study evaluated the clinical utility of
incorporating the novel SharkCore® needle into the
evaluation of patients with known or suspected NETs.
Our preparations with the SharkCore® needle allowed
for simultaneous cytology material (touch or squash
preps) in all cases, diagnostic core biopsy/core fragment
material in a significant proportion of cases (8/10),
and stainable lesional cell block material in all
cases (allowing for delineation of immunohistochemical
markers to prove neuroendocrine differentiation).
The quantity of diagnostic material in cell blocks
provided by the SharkCore® needle, to go along with
the standard cytomorphologic features compatible with
NETs, enabled the pathologist to render a definitive
report of NET in 9/10 cases.
A comparison group of the same number of patients
with known or suspected NETs who underwent
EUS‑FNA with a standard 22‑gauge needle had the
same retrospective evaluation performed. While the
cytologic preparations were equivalent in this group
when compared to the SharkCore® group, four of the
ten cell blocks lacked any lesional material for further
immunohistochemical evaluation (markers to prove
neuroendocrine differentiation). This resulted in a trend
toward less definitive interpretations in this group as
only 5/10 (50%) of these patients received a definitive

Figure 2. Diff‑Quik ® stained aspirate smear from a case using
the standard needle showing characteristic cytologic features of
neuroendocrine tumor. Specifically, a somewhat monotonous
proliferation of loosely clustered cells with plasmacytoid features (×20)
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Figure 3. Diff‑Quik® stained touch preparation from a case using
the SharkCore® needle showing characteristic cytologic features
of neuroendocrine tumor. Specifically, a somewhat monotonous
proliferation of loosely clustered cells with plasmacytoid features (×20)

diagnosis of NET in the pathology report. Along the
same lines, a recent study by Dwyer et al. conducted on
56 intra‑abdominal masses comparing standard EUS
needles to a biopsy type needle also showed more
material for ancillary studies for the biopsy needle
type.[12]
Another notable finding is our result that the cytologic
material garnered on site by the SharkCore ® needle
allowed for significantly fewer passes to reach specimen
adequacy (P = 0.0074). The reduction in the number
of needle passes to reach adequacy was nearly 2‑fold
less with the SharkCore® (average 1.5 passes/case) versus
the standard needle (2.9 passes/case). This parallels our
findings from our recent pilot study comparing the
SharkCore® to the conventional needle in a cohort of
thirty patients.[7]
While the standard cytologic morphologic analysis
functions well in the majority of EUS FNAs performed
on solid pancreatic lesions, a subset of these lesions
present diagnostic dilemmas when tissue obtained
is analyzed using cytologic preparations (such as
aspirate smears) alone. Pancreatic NETs are one such
entity where having a robust cell block for ancillary
studies is critical to navigate the primary differential
diagnosis between NETs, acinar cell carcinomas,
solid pseudopapillary neoplasms, and even metastatic
melanoma or plasma cell dyscrasias.[11]
In a recent retrospective study of patients with
histologically confirmed pancreatic NETs who had
prior EUS‑FNAs performed, Chen et al. found that

a definitive diagnosis of NET was only able to be
rendered on 13/21 (61.9%) of EUS‑FNA specimens.
Each of the 13 cases that had a definitive diagnosis
had adequate cell block material obtained for ancillary
testing, underpinning the need for robust cell block
material to render a conclusive determination of a
pancreatic NET.[13] In addition, Deshpande and Lauwers
in their evaluation of pancreatic NETs with a cystic
component highlighted the potential cytomorphologic
overlap of cystic NETs with adenocarcinoma. In their
review of histologically confirmed cases of cystic NETs,
three of the five were misdiagnosed on EUS‑FNA
as either adenocarcinoma or atypical glandular cells
(a term that can be taken by a clinician as suspicious
for adenocarcinoma). The authors suggested that
appropriate immunostaining of cell block material
would help avoid this potential pitfall as none of the
miscategorized cases had cell block material available at
the time of diagnosis.[14] Conversely, in a recent 15‑year
retrospective study conducted at our own institution,
8 of the 26 (30%) false‑positive EUS‑FNA diagnoses
of adenocarcinoma proved to be NETs on resection.
In fact, NETs accounted for the most common cause
of false‑positive adenocarcinomas in this study.[10] It is
worth noting that this study was performed before the
introduction of the SharkCore® needle at our institution.
Limitations of this study include its single center and
retrospective nature. To date, there is very limited
published literature on the SharkCore® needle, and this
study represents the first on the SharkCore® needle as
it functions in the role of diagnosing NETs. Larger
studies, multicenter studies, and studies comparing the
device to other EUS‑FNA needles as well as needles
designed to obtain a core sample are warranted.
EUS needles continue to be an area of development.
The desire to possess a needle that is easy for the
endoscopist to maneuver, inexpensive, and has the
ability to obtain histologic core tissue in selected cases
where ancillary studies are needed by the pathologist
has been longstanding. Our pilot investigation targeting
patients with known or suspected pancreatic NETs
indicates that the SharkCore® needle shows promise in
obtaining suitable tissue for ancillary testing that can
allow for more definitive pathologic interpretations on
EUS‑FNA specimens.
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